Patent intelligence · US
US 10314824
Compositions and methods of treating cardiac fibrosis with ifetroban
Compositions and methods of treating cardiac fibrosis with ifetroban
Patent details — US 10314824
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 11, 2019
- Expiration
- Jun 6, 2039
- Applicant
- Cumberland Pharmaceuticals Inc.
- Claims
- 9
- CPC classes
- A61K, A61K31/421, A61K31/422, A61K9/00
Quick answer
US 10314824 (Compositions and methods of treating cardiac fibrosis with ifetroban) is held by Cumberland Pharmaceuticals Inc.. Status: granted. Granted Jun 11, 2019. Expires Jun 6, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cumberland Pharmaceuticals Inc.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/421, A61K31/422, A61K9/00, A61K9/0019, A61K9/2059
More from Cumberland Pharmaceuticals Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12161632
Compositions and methods of treating cardiac fibrosis with ifetroban
granted -
US 11806400
Injectable ibuprofen formulation
granted -
US 11571412
Thromboxane receptor antagonists in AERD/asthma
granted -
US 10925860
Compositions and methods of treating cardiac fibrosis with ifetroban
granted -
US 10751383
Doses and methods for administering telavancin
granted -
US 10583126
Compositions and methods of treating cardiac fibrosis with ifetroban
granted -
US 10456380
Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists
granted
Frequently asked questions
What is US patent 10314824?
US 10314824 (Compositions and methods of treating cardiac fibrosis with ifetroban) is held by Cumberland Pharmaceuticals Inc.. Status: granted. Granted Jun 11, 2019. Expires Jun 6, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10314824?
Cumberland Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.
When does US 10314824 expire?
Our index shows an expiration date of Jun 6, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.